Journal: Bioactive Materials

Article Title: A composite hydrogel enables the spatiotemporal delivery of distinct cytokines to drive the native vascularized bone regeneration

doi: 10.1016/j.bioactmat.2026.02.048

Figure Lengend Snippet: Full fabrication and application schematic diagram of GelMA-VEGF/ECM-PCSK9 composite hydrogel and the related signaling pathway of PCSK9 that promotes BMSC osteogenic differentiation.

Article Snippet: VEGF, ELISA kit for VEGF and PCSK9 were purchased from Boster company (Wuhan, China).

Techniques:

Journal: Bioactive Materials

Article Title: A composite hydrogel enables the spatiotemporal delivery of distinct cytokines to drive the native vascularized bone regeneration

doi: 10.1016/j.bioactmat.2026.02.048

Figure Lengend Snippet: Construction and characterization of GelMA-VEGF/ECM-PCSK9 composite hydrogel. A Schematic diagram showing the process of composite hydrogel construction; B) Photographs of GelMA-VEGF hydrogel and GelMA-VEGF/ECM-PCSK9 hydrogel formation after UV light respectively; C i) Electron microscopic image of pure GelMA hydrogel, with a scale of 100 μm; ii) Enlarged electron microscopic image of GelMA hydrogel, with a scale of 50 μm; D) i The electron microscope image of the combination of GelMA hydrogel and ECM, with a scale of 100 μm; ii Electron microscope magnified image of GelMA hydrogel combined with ECM, with a scale of 50 μm; E) The infrared spectrum (FITR) diagram of the acellular ECM, GelMA hydrogel and GelMA/ECM composite hydrogel contains common basic energy groups; F) Load rate of PCSK9 in ECM; G) Release rate of VEGF loaded with GelMA hydrogel and GelMA/ECM composite hydrogel respectively; H) Release rate of PCSK9 loaded with ECM and GelMA/ECM composite hydrogel respectively; I) Release rate of VEGF and PCSK9 loaded in GelMA and GelMA/ECM on different time points respectively; J) Release rate of VEGF and PCSK9 respectively when loaded in GelMA/ECM; K) The swelling rate of GelMA gel and GelMA/ECM composite gel dissolved in PBS (n = 6); L) Degradation rate of GelMA hydrogel and GelMA/ECM composite gel in vitro (n = 6).∗means that compared with the control group, p < 0.05; ∗means that compared with the control group, p < 0.01; ∗∗∗means that compared with the control group, p < 0.001.

Article Snippet: VEGF, ELISA kit for VEGF and PCSK9 were purchased from Boster company (Wuhan, China).

Techniques: Microscopy, In Vitro, Control

Journal: Bioactive Materials

Article Title: A composite hydrogel enables the spatiotemporal delivery of distinct cytokines to drive the native vascularized bone regeneration

doi: 10.1016/j.bioactmat.2026.02.048

Figure Lengend Snippet: Angiogenic capacity formulations of HUVECs in response to different composite biomaterial in vitro. A) Calcein/PI staining of HUVECs seeded on glass slides, showing the cell migration profiles of HUVECs treated with different material groups, scale bar = 200 μm; B) Quantitative analysis of the intercellular blank areas in each group, with the baseline group serving as the negative control; C) Angiogenic images of HUVECs co-cultured with different composite materials for 4 h and 8 h respectively, scale bar = 250 μm; D–G) Quantitative assessment of angiogenic capacity in each group via ImageJ software analysis of key angiogenic parameters. Abbreviations: NC = negative control group; V = exogenous VEGF protein-only group; GV=GelMA + exogenous VEGF protein group; GVE = GelMA + VEGF + ECM group; GVEP= GelMA/VEGF + ECM/PCSK9 group. Statistical notations: ∗∗means that compared with the control group, p < 0.01; ns = no significant difference between group.

Article Snippet: VEGF, ELISA kit for VEGF and PCSK9 were purchased from Boster company (Wuhan, China).

Techniques: In Vitro, Staining, Migration, Negative Control, Cell Culture, Software, Control

Journal: Bioactive Materials

Article Title: A composite hydrogel enables the spatiotemporal delivery of distinct cytokines to drive the native vascularized bone regeneration

doi: 10.1016/j.bioactmat.2026.02.048

Figure Lengend Snippet: The effect of different composite hydrogel on the osteogenic differentiation of BMMSC in vitro. Cultivate BMMSC for osteogenic differentiation in osteogenic medium with GelMA, GelMA-VEGF, GelMA-VEGF/ECM, ECM-PCSK9, and GelMA-VEGF/ECM-PCSK9 for 7 days respectively. A,B) The cell nucleus was stained with DAPI (blue), RUNX2 was stained with RUNX2 antibody (green), and COL1A1 was stained with COL1A1 antibody (red), with a scale bar of 200 μm. C,D) The quantitative analysis results of COL1A1 and RUNX2 immunofluorescence images; E,F) Quantitative analysis of ALP staining and ARS staining for BMMSC co-culture with different kinds of hydrogels; G) ALP staining result for BMMSC co-culture with different kinds of hydrogels for 7days, scale bar = 200 μm; F) ARS staining result for BMMSC co-culture with different kinds of hydrogels for 14days, scale bar = 200 μm; I, J) After 7 and 14 days of co-culture with different combinations of composite hydrogels and BMMSC for osteogenesis and differentiation, the PCR experiment results of osteogenesis related indicators suggest that compared with the control group. G = simple GelMA hydrogel group, GV=GelMA hydrogels + VEGF protein group, GV/E = GelMA + VEGF/ECM group, EP = ECM + PCSK9 protein group, GVEP=GelMA + VEGF/ECM + PCSK9 protein group, the significant differences between the groups are expressed as ∗ p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ns means there is no significant difference between the groups.

Article Snippet: VEGF, ELISA kit for VEGF and PCSK9 were purchased from Boster company (Wuhan, China).

Techniques: In Vitro, Staining, Immunofluorescence, Co-Culture Assay, Control

Journal: Bioactive Materials

Article Title: A composite hydrogel enables the spatiotemporal delivery of distinct cytokines to drive the native vascularized bone regeneration

doi: 10.1016/j.bioactmat.2026.02.048

Figure Lengend Snippet: After adding different concentrations of PCSK9 to BMMSC for osteogenic induction, western blotting (WB) experiment was performed to evaluate the expression of phosphorylated proteins and total proteins among different osteogenic differentiation relevant signaling pathways. A) WB images of different signaling pathways that related to osteogenic differentiation after adding different concentrations of PCSK9; B-D) Quantitative analysis results of phosphorylated protein and total protein. Compared with the control group, ∗ means p < 0.05, ∗∗ means p < 0.01.

Article Snippet: VEGF, ELISA kit for VEGF and PCSK9 were purchased from Boster company (Wuhan, China).

Techniques: Western Blot, Expressing, Protein-Protein interactions, Control

Journal: Bioactive Materials

Article Title: Glucose/ROS-responsive and redox-gated adaptive hydrogel dressing for accelerating diabetic wound repair via synergistic cGAS/STING pathway inhibition and oxidative stress alleviation

doi: 10.1016/j.bioactmat.2026.03.025

Figure Lengend Snippet: Angiogenesis and collagen deposition in diabetic wound tissues following HPSL@SG hydrogel treatment. (A) Dihydroethidium (DHE) immunofluorescence staining and (B) semi-quantitative analysis of wound tissues from each treatment group on day 7, scale bar = 100 μm. Immunofluorescence staining of (C) MMP-9, IL-6, and IL-10, and (D) CD31, VEGF-A, and collagen I in wound tissue sections from each treatment group on day 7, scale bar = 100 μm. (E-J) Mean relative fluorescence intensity of each indicator in wound tissue sections from each treatment group on day 7, scale bar = 100 μm. All data are shown as mean ± SEM (n = 6).

Article Snippet: IL-6 and IL-10-specific antibodies were purchased from Bosterbio (Wuhan, China).

Techniques: Immunofluorescence, Staining, Fluorescence

Journal: Brain, Behavior, & Immunity - Health

Article Title: Exploring the role of PD-1 as a marker in drug-refractory epilepsy and its potential indication for valproic acid treatment

doi: 10.1016/j.bbih.2026.101238

Figure Lengend Snippet: Elevated PD-1 expression and altered cytokine levels in plasma of IE patients. (A) PD-1 expression on CD4 + CD25 high Tregs is significantly increased in IE patients, particularly in the ISE subgroup, while CD4 + and CD4 + CD25 + T cell percentages are reduced. (B) Plasma concentrations of IL-10 and IL-6 are elevated in IE patients, with IL-10 showing a progressive increase with seizure severity. (C) Correlation analyses reveal associations between immune parameters and clinical characteristics. ∗∗∗P < 0.001, ∗∗ P < 0.01, ∗ P < 0.05; ns indicates not significant.

Article Snippet: Concentrations of IL-10 and IL-6 in plasma and CSF were quantified using commercial double-antibody sandwich ELISA kits (Boster Bioengineering, China), according to the manufacturer's instructions.

Techniques: Expressing, Clinical Proteomics

Journal: Brain, Behavior, & Immunity - Health

Article Title: Exploring the role of PD-1 as a marker in drug-refractory epilepsy and its potential indication for valproic acid treatment

doi: 10.1016/j.bbih.2026.101238

Figure Lengend Snippet: Central nervous system immune activation in ISE patients. (A) PD-1 + CD4 + CD25 high Treg cell counts are significantly elevated in the CSF of ISE patients compared to controls. (B) Both IL-10 and IL-6 concentrations are increased in the CSF of ISE patients. (C) Age correlates positively with PD-1 + CD4 + CD25 low and CD4 + CD25 high Treg percentages, and negatively with CD4 + T cell percentage in the CSF of ISE patients. ∗∗∗P < 0.001, ∗∗P < 0.01, ∗P < 0.05.

Article Snippet: Concentrations of IL-10 and IL-6 in plasma and CSF were quantified using commercial double-antibody sandwich ELISA kits (Boster Bioengineering, China), according to the manufacturer's instructions.

Techniques: Activation Assay

Journal: Brain, Behavior, & Immunity - Health

Article Title: Exploring the role of PD-1 as a marker in drug-refractory epilepsy and its potential indication for valproic acid treatment

doi: 10.1016/j.bbih.2026.101238

Figure Lengend Snippet: VPA treatment modulates PD-1 expression and IL-10 levels independently of drug concentration. (A) Plasma PD-1 expression on both CD4 + CD25 high and CD4 + CD25 low Treg subsets decreases significantly after 48 h of VPA treatment. (B) Plasma IL-10 levels decrease significantly after VPA treatment, while IL-6 shows no significant change. (C) Seizure control time correlates with immunological parameters but not with VPA concentrations. (D) VPA concentrations in CSF are significantly lower than in plasma, with no change between d0 and d3, and no correlation with seizure control time. ∗∗∗P < 0.001, ∗∗P < 0.01, ∗P < 0.05; ns indicates not significant.

Article Snippet: Concentrations of IL-10 and IL-6 in plasma and CSF were quantified using commercial double-antibody sandwich ELISA kits (Boster Bioengineering, China), according to the manufacturer's instructions.

Techniques: Expressing, Concentration Assay, Clinical Proteomics, Control